Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes. by MacLeod, Daniel T et al.
UC San Diego
UC San Diego Previously Published Works
Title
Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.
Permalink
https://escholarship.org/uc/item/9xq1w0dc
Journal
The Journal of investigative dermatology, 135(1)
ISSN
0022-202X
Authors
MacLeod, Daniel T
Nakatsuji, Teruaki
Wang, Zhenping
et al.
Publication Date
2015
DOI
10.1038/jid.2014.330
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Vaccinia virus binds to the scavenger receptor MARCO on the 
surface of keratinocytes
Daniel T. MacLeod1, Teruaki Nakatsuji1,2, Zhenping Wang1, Anna di Nardo1, and Richard L. 
Gallo1,2
1Division of Dermatology, Department of Medicine, University of California - San Diego, La Jolla, 
CA, USA, 92093
2Veterans Affairs San Diego Health Care System, San Diego, CA, USA 92161
Abstract
Patients with altered skin immunity, such as individuals with atopic dermatitis (AD), can have a 
life-threatening disruption of the epidermis known as eczema vaccinatum (EV) after vaccinia virus 
(VV) infection of the skin. Here, we sought to better understand the mechanism(s) by which VV 
associates with keratinocytes. The class A scavenger receptor known as MARCO (macrophage 
receptor with collagenous structure) is expressed on human and mouse keratinocytes and found to 
be abundantly expressed in the skin of patients with AD. VV bound directly to MARCO, and 
overexpression of MARCO increased susceptibility to VV infection. Furthermore, ligands with 
affinity for MARCO, or excess soluble MARCO, competitively inhibited VV infection. These 
findings indicate that MARCO promotes VV infection and highlights potential new therapeutic 
strategies for prevention of VV infection in the skin.
Introduction
Vaccinia virus (VV) is a large DNA virus widely known for its use as a vaccine for the 
closely related variola virus, the causative agent of smallpox (Copeman and Banatvala, 
1971; Fulginiti et al., 2003a). Routine administration of this vaccine was stopped after 
smallpox was eradicated, however VV has been utilized for vaccination of selected high-risk 
individuals such as some individuals serving in the military (Fulginiti et al., 2003a), and to 
study the disease mechanisms of smallpox. Vaccination is accomplished by inoculation in 
the skin by scarification of the epidermis. Inoculation typically results in a localized VV 
infection of keratinocytes at the inoculation site. This usually resolves following local innate 
immune defense and subsequent development of protective humoral and cell-mediated 
immunity. However, individuals with altered skin immunity, such as those with AD, are at 
increased risk of developing severe reactions to inoculation with VV, such as the 
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disseminated skin infection eczema vaccinatum (EV) (Copeman and Wallace, 1964; 
Fulginiti et al., 2003b). Immunocompromised patients and children are also at risk of 
developing severe infections with VV (Lane and Millar, 1969; Redfield et al., 1987; 
Sepkowitz, 2003). While these individuals are excluded from vaccination due to the 
associated risks, severe infections have also been known to occur in individuals coming into 
contact with others who have been recently inoculated with VV (Lane et al., 1970; Vora et 
al., 2008).
Although treatments for VV infection exist, none have been fully evaluated in a controlled 
setting (Bray, 2003). A better understanding of the factors controlling the pathogenesis of 
VV in the skin would reduce complications resulting from inoculation with live VV, and 
may also hint to alternative strategies for treatment of other viruses that share these 
pathogenic mechanisms. Some of the most important cellular factors that determine the 
outcome of contact with VV include receptors that are utilized by the virus to bind to and 
infect target cells, and alternatively, innate immune receptors that act to detect the virus and 
initiate immune responses. While some previous studies have been dedicated to examining 
these issues, few have done so using keratinocytes, the primary target of VV infection in the 
skin.
A number of cell surface molecules have been previously identified to mediate VV 
adsorption to the cell surface and promote infection. Some strains of VV bind initially to 
heparan sulfate (HS) or chondroitin sulfate (CS) glycosaminoglycans (GAGs), but others 
infect cells in a GAG-independent manner (Bengali et al., 2009). Five viral proteins have 
been identified so far for their involvement in binding to the cell surface. A27 and H3 
mediate binding to HS while D8 binds to CS (Chung et al., 1998; Hsiao et al., 1999; Lin et 
al., 2000). GAG-independent binding is also possible with certain strains and certain cell 
types, and involves interactions between A26 and laminin on the cell surface, or between L1 
and an undetermined receptor (Chiu et al., 2007; Foo et al., 2009). The mechanisms of 
membrane fusion are complex, requiring at least 11 proteins on the surface of VV, and 
specific cellular proteins involved in this process have not yet been identified (Bengali et al., 
2009). Studies focusing specifically on keratinocytes are required to determine which 
surface molecules are most critical for VV infection.
Cell surface and intracellular receptors are key elements of the innate immune system and 
are primarily thought to serve a protective role, as defects in innate immunity appear to be 
critical to pathogenesis of EV (Howell et al., 2006a; Howell et al., 2004; Howell et al., 
2007; Howell et al., 2006b; Kim et al., 2007). Additionally, numerous proteins expressed by 
VV function to interfere with host defense responses (reviewed in (Haga and Bowie, 2005)). 
Keratinocytes are fully competent innate immune cells, expressing a number of receptors 
capable of detecting infection by pathogens such as VV, and can respond with the 
production of a number of antimicrobial mediators (Kristian et al., 2003; Nizet et al., 2001; 
Schauber et al., 2007). Cells can detect VV infection through activation of cell-surface and 
intracellular pattern recognition receptors (PRRs) such as the toll-like receptors (TLRs). 
Keratinocytes express TLRs 1–6, 9, and 10 (Köllisch et al., 2005; Lebre et al., 2006). A 
previous study implicated TLR2/6 in detection of VV on the cell surface, and melanoma 
differentiation-associated gene-5 (MDA-5) and the NOD-like receptor family, pyrin domain 
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containing 3 (NALP-3) inflammasome detecting VV inside the cell (Delaloye et al., 2009). 
Additionally, VV DNA can stimulate innate immune responses in cells after recognition by 
TLR8 (Martinez et al., 2010). Furthermore, Sphingosine-1-phosphate receptor 2 has recently 
been shown to recognize lipids derived from viral membranes and trigger the release of 
antimicrobial peptides (Wang et al., 2012). Further experiments are needed to know which 
of these innate immune receptors are most critical for keratinocyte responses to VV 
infection.
Class A scavenger receptors have important roles in innate immune defense as they bind to 
extracellular viral dsRNA and mediate uptake and presentation of dsRNA to TLR3 in the 
endosome (DeWitte-Orr et al., 2010a; Limmon et al., 2008; Matsumoto et al., 2003; 
Mukhopadhyay et al., 2011; Saleh et al., 2006; Yew et al., 2010). TLR3 is hypothesized to 
enable recognition of a DNA virus such as VV since virtually all viruses produce dsRNA at 
some point during replication (Jacobs and Langland, 1996), which is then released into the 
extracellular space after lysis of infected cells (Majde et al., 1998). Scavenger receptors 
have also been shown to bind to a variety of bacterial and viral products (Krieger et al., 
1993; Yew et al., 2010). Therefore, it would be expected that scavenger receptors would 
function to alert keratinocytes to danger from VV infection and provide a protective role. 
However we previously identified that keratinocytes express the class A scavenger receptor 
MARCO, and found that despite the role of this receptor in the innate immune system, 
MARCO is exploited by herpes simplex virus type 1 (HSV-1) to bind to the surface of 
keratinocytes and increase infection (Macleod et al., 2013). In this manuscript, we 
hypothesized that MARCO may also serve to enhance VV infection of keratinocytes. Our 
findings suggest MARCO can play a significant role in infection of keratinocytes, and that 
this interaction could have important implications for eczema vaccinatum.
Results
MARCO is abundantly expressed in the skin of patients with atopic dermatitis
Patients with AD are susceptible to severe infections with VV (Copeman and Wallace, 
1964; Howell et al., 2006a; Howell et al., 2004). We recently found that MARCO is 
expressed in keratinocytes and is a key receptor in cutaneous HSV-1 infection (Macleod et 
al., 2013). Thus, given the susceptibility of AD patients to HSV-1 and VV, we decided to 
investigate whether the expression of MARCO in AD could have a role in the pathogenesis 
of these viral skin disorders. First, we tested the expression of MARCO in normal skin 
compared to lesional and non-lesional AD skin. MARCO was expressed evenly throughout 
the epidermis of normal skin and non-lesional AD skin (Figure 1a,b, and Supplementary 
Fig. S1). Strikingly, much greater staining for MARCO was seen in the epidermis of AD 
lesional skin. These data confirmed that the skin of AD has abundant MARCO on the 
surface of keratinocytes that could potentially interact with VV and play a role in the 
susceptibility of individuals with AD to VV infection. Stimulation of cultured normal human 
keratinocytes with cytokines elevated in AD (IL-4 and IL-13) did not significantly alter 
MARCO expression (Fig. 1c), suggesting that other factors contributing to AD were 
responsible for the increased MARCO expression.
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Vaccinia virus binds directly to MARCO
We next sought to identify if MARCO is capable of interacting with VV. Keratinocytes 
express both MARCO and OLR1 scavenger receptors (Macleod et al., 2013). To test for a 
direct interaction with VV, we employed a cell-free ELISA utilizing purified recombinant 
MARCO. Using this assay, we found that VV bound specifically to immobilized human and 
mouse MARCO protein (Fig. 2a,b), demonstrating that VV binds to MARCO in the absence 
of any other cell surface receptors. Importantly, this interaction could be disrupted by the 
addition of Poly(I) (Fig. 2c), a scavenger receptor ligand known to bind to MARCO (Chen 
et al., 2006; Kodama et al., 1990; Moriwaki et al., 1998). VV did not bind to two additional 
scavenger receptors, OLR1 (Fig 2d) and MSR1 (Fig 2e), and an alternative enveloped virus, 
an HIV-1 pseudovirus (PsV), did not bind to MARCO (Fig. 2f).
Overexpression of MARCO increases susceptibility to VV infection
To evaluate the functional significance of the interaction of VV and MARCO we next 
infected wild-type (WT) and MARCO−/− mice with VV. Interestingly, both WT and 
MARCO−/− mice infected with VV had significant and comparable infiltration of 
inflammatory cells around the wound edge and throughout the dermis compared to 
uninfected control mice, and lesion sites appeared morphologically similar to each other 
(Figure 3a). Furthermore, at six days post-infection, there was no significant difference in 
the sizes of wounds in the skin of WT and MARCO−/− mice (Figure 3b), indicating that 
MARCO expression is not absolutely required for VV infection. However, although 
MARCO did not appear to be essential for infection in whole skin and the absence of 
MARCO did not alter the morphology of VV-induced lesions, it remained possible that the 
lack of MARCO could be compensated by additional receptors with similar characteristics. 
Thus, to further examine the relationship between the expression of MARCO and 
susceptibility to VV infection, we utilized a keratinocyte cell line that stably overexpresses 
human MARCO protein at levels approximately 3 fold higher than control transfected cells 
(Macleod et al., 2013). VV infection of these cells resulted in significantly more viral 
plaques (Figure 3b) and viral DNA (Figure 3c) in the cells that overexpress MARCO 
compared to control cells. These experiments demonstrated that the interaction between 
MARCO and VV is functionally significant.
Scavenger receptor antagonists inhibit vaccinia virus infection of keratinocytes
A number of studies have previously demonstrated that there is overlap in the binding 
specificities and functions of class A scavenger receptors (DeWitte-Orr et al., 2010b; 
Limmon et al., 2008). Thus, as discussed above, the presence of additional receptors with 
similar specificity, such as SCARA3, COLEC12, or SCARF1, which are expressed by 
NHEK (Macleod et al., 2013), may compensate for the absence of MARCO in MARCO−/− 
mice. In this instance, scavenger receptors ligands that exploit a similar binding specificity 
between MARCO and other such receptors would be able to competitively inhibit binding to 
VV. Polyinosinic acid (Poly(I)) and dextran sulfate (Dxs) are two such ligands that have 
been extensively characterized as ligands for class A scavenger receptors (Krieger et al., 
1993). Both of these compounds potently inhibited VV infection of keratinocytes in a dose-
dependent manner (Figure 4a,b). Poly(I) provided levels of protection comparable to 
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Poly(I:C), which also binds to scavenger receptors (DeWitte-Orr et al., 2010a; Limmon et 
al., 2008; Mukhopadhyay et al., 2011; Saleh et al., 2006). However, unlike Poly(I:C), 
Poly(I) is not able to activate innate immune responses in keratinocytes (Macleod et al., 
2013). In contrast, the similar nucleic acid Poly(C), does not bind to scavenger receptors and 
had no effect on VV infection (Fig. 4a). Thus, these results showed a strong correlation 
between scavenger receptor binding and the capacity to inhibit infection. In light of the 
absence of an interaction of VV with OLR-1 and MSR1 (Fig. 2d,e), this revealed that while 
not all receptors that bind Poly(I) bind to VV, Poly(I) interferes with binding of VV to the 
cell surface.
Although the similarities in the capacity of Poly(I:C) and Poly(I) to prevent VV infection 
indicated that the inhibition could be attributed to a shared affinity for scavenger receptors 
rather than the ability of Poly(I:C) to activate keratinocyte innate immune responses, we 
designed experiments to confirm this. We first compared the ability of treatment of 
Poly(I:C) and other TLR ligands to protect against VV infection. Poly(I:C), significantly 
protected against VV infection of keratinocytes but treating with ligands that activate other 
TLRs (Lai and Gallo, 2008) did not (Fig. 4c). Notably, this inhibitory effect by Poly(I:C) as 
measured by viral plaque formation was dose-dependent and was comparable in both HaCat 
keratinocytes and normal human epidermal keratinocytes (NHEK) (Fig. 4d,e). This 
inhibitory effect was also seen when analyzing the amount of VV early gene mRNA at an 
early timepoint after infection (Fig. 4f), indicating that the inhibition was occurring at an 
early step in the infectious process.
To also test if protection by Poly(I:C) could be attributed to activation of innate immune 
responses, we treated cells with inhibitors of cellular activation. First, we used 
cycloheximide (Chx), a potent inhibitor of new protein synthesis. Treatment with Chx 
inhibited the ability of the cells to synthesize new proteins by 97% (Data not shown). 
However, VV early gene expression is, by definition, not altered by Chx treatment, thus 
allowing us to evaluate the ability of the virus to enter cells and begin viral RNA synthesis 
under conditions that block synthesis of new proteins (Amegadzie et al., 1991). Poly(I:C) 
inhibited VV infection even under these conditions (Supplementary Fig. S2a), indicating 
that the protective effect of Poly(I:C) did not involve the synthesis of new antiviral effector 
proteins. Next, we tested the effect of treatment with chloroquine (CQ), a potent inhibitor of 
endosomal acidification. These conditions prevent the ability of Poly(I:C) to induce IL-6 and 
IFN-β by more than 80% (Macleod et al., 2013). Poly(I:C) was able to protect against VV 
infection in keratinocytes treated with CQ at levels comparable to the protection seen in 
untreated cells (Supplementary Fig. S2b), further demonstrating that cellular activation by 
Poly(I:C) was not required for the protective effect of Poly(I:C). These results with both Chx 
and CQ also confirmed that the protective activity of Poly(I:C) occurred at a very early 
timepoint during infection.
To complement these studies, we tested the ability of soluble recombinant MARCO to 
inhibit VV infection. Pretreatment with recombinant MARCO inhibited VV plaque 
formation in NHEK by 54% (Fig. 4g, P < 0.001), suggesting that the binding of MARCO to 
VV inhibits association of the virus with MARCO and related scavenger receptors on the 
cell surface, confirming the necessity of these molecules for optimal infection of skin cells.
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Finally, to test the significance of blocking scavenger receptors to cutaneous VV infection, 
we topically applied a single dose of Poly(I) to the back skin of mice prior to infecting them 
with VV. This single dose of Poly(I) moderately reduced wound size at day 6 post-infection, 
while Poly(C) treated mice had wound sizes comparable to control PBS-treated mice (Fig. 
4h).
These results demonstrated that multiple compounds that share the capacity to restrict access 
to cell-surface scavenger receptors are capable of inhibiting VV infection in vitro and in 
vivo, and further confirmed that the binding interactions observed between VV and MARCO 
are functionally relevant.
Discussion
We demonstrate in this manuscript that VV binds directly to MARCO, a scavenger receptor 
present on the surface of keratinocytes. Importantly, overexpression of MARCO increased 
susceptibility to VV infection, recombinant MARCO inhibited infection of keratinocytes, 
and ligands capable of blocking this interaction potently prevented infection of VV in 
keratinocytes and mouse skin. These results identify MARCO as a receptor that can be used 
by VV during infection in the skin. These observations also show a potential new 
therapeutic approach that may help limit VV infection in patients with AD who have 
abundant expression of MARCO in their thickened lesional epidermis.
A number of studies suggest that multiple receptors play complementary roles to enable VV 
binding, thus providing a complex and partially redundant system for the virus to infect a 
variety of cell types. One such class of molecules to which VV binds is cell surface heparan 
sulfate proteoglycans (HSPGs). MARCO was recently shown by us to act in conjunction 
HSPGs to mediate adsorption of HSV-1 to the cell surface (Macleod et al., 2013). Based on 
our current results, we believe that a similar mechanism is functioning for VV. Furthermore, 
in addition to having multiple molecules to adhere to on the host cell, the strain of virus and 
the type of cell being infected also result in differences in the adsorption and entry of VV. 
Some strains of VV exhibit less dependence on HSPGs for adsorption compared to other 
strains (Bengali et al., 2009; Carter et al., 2005). To dissect the strain differences in viral 
binding it is therefore important to understand the molecules on the surface of the virus that 
are mediating adsorption. The viral preparation used in our experiments was primarily the 
intracellular mature virus (IMV) form of VV, which has at least seven proteins known or 
predicted to be expressed or associated with the cell surface (Duke-Cohan et al., 2009). The 
interaction with MARCO was possibly mediated by the viral glycoproteins H3, A27, D8, all 
of which are present on the surface of IMV and have been shown to have roles in the 
adsorption of VV by interactions with glycosaminoglycans (GAGs) (Chung et al., 1998; 
Hsiao et al., 1999; Lin et al., 2000). It is also possible that another viral glycoprotein, such 
as A26, which binds to laminin (Chiu et al., 2007) is also involved in binding to MARCO. 
The L1 protein is another interesting possibility, as this viral protein has been shown to bind 
to cell surfaces and blocks infection of VV in a GAG-independent manner by binding to an 
unidentified cellular receptor (Foo et al., 2009). Further experiments will be needed to 
identify the specific viral glycoprotein capable of interacting with scavenger receptors, and 
to confirm whether the primary role of these receptors is solely in adsorption of the virus to 
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the cell surface, or whether they have an active role in uptake of the virus as well. VV is 
taken up by target cells via macropinocytosis, utilizing phosphatidylserine (PS) in the viral 
membrane to mimic apoptotic debris and trigger uptake by a cellular PS receptor (Laliberte 
and Moss, 2009; Mercer and Helenius, 2008; Mercer et al., 2010). It is possible that 
scavenger receptors are contributing to this process as well, however further experiments 
will be needed to test this possibility.
Previously, it was expected that scavenger receptors serve a protective role due to their 
capacity to facilitate the detection of foreign pathogens. However, we have now 
demonstrated that MARCO increases the susceptibility to infection by binding to VV. This 
is consistent with a previously described interaction between HSV-1 and MARCO (Macleod 
et al., 2013), and the binding of the closely related scavenger receptor MSR1 to Adenovirus 
5 (Haisma et al., 2009). This finding that an increasing number of diverse viruses exploit 
class A scavenger receptors is very interesting. It is also possible that these viruses use 
scavenger receptors as a way to escape recognition by the innate immune system. Indeed, it 
has been shown that although MSR1 and MARCO enhance uptake of extracellular 
Pathogen-associated molecular patterns (PAMPs) for recognition by intracellular PRRs, the 
presence of these receptors actually inhibits recognition of extracellular PAMPs by cell 
surface PRRs, limiting the subsequent activation of cell surface innate immune defenses 
(Mukhopadhyay et al., 2011). Additionally, although class B scavenger receptors differ from 
the class A scavenger receptors in terms of structure and function, a number of these 
receptors have also been identified as receptors for viruses including Hepatitis C virus 
(Scarselli et al., 2002), Coxsackie A virus -7, -14, and -16 (Yamayoshi et al., 2012) and 
Enterovirus 71 (Yamayoshi et al., 2009).
The significant inhibition of VV by scavenger receptor ligands in human cells and mouse 
skin is important, as this shows that these ligands could potentially be used to block 
scavenger receptors and limit VV infection in human skin. Currently, treatment of severe 
cutaneous VV infection can involve administration of vaccinia immune globulin (VIG), 
however VIG is currently classified by the CDC as an investigational drug, and controlled 
studies determining the true efficacy of VIG and other potentially useful antiviral drugs such 
as Cidofovir and Riboviron are lacking (Bray, 2003). Although these treatments appear to 
reduce the severity of infection, EV is still a life-threatening infection that could benefit 
from additional therapeutics. Furthermore, it is likely that a combination of approaches to 
target multiple aspects of the pathophysiology of VV infection would be the most effective 
therapy. For example, it has been shown that combined therapy of Poly(I:C) and VIG is 
more effective to treat severe VV infection in mice than either treatment alone (Worthington 
and Baron, 1973). Thus, developing optimal treatments may require a combination of 
strategies to block viral binding, entry, and replication, in addition to utilizing VIG to 
neutralize viral particles. Blocking access to MARCO may thus be an important component 
of future approaches to antiviral therapy. Further studies will be needed to optimize 
treatment conditions and fully evaluate the efficacy of scavenger receptor blockade as a 
treatment for severe infections such as EV that arise as complications from inoculation with 
VV.
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Materials and Methods
Cells and Viruses
NHEK were cultured in Epilife media containing Epilife Defined Growth Supplement (Life 
Technologies, Grand Island, NY), 0.06mM calcium chloride, and 100 I.U. Penicillin and 
100μg Streptomycin per ml (VWR, Radnor, PA). BSC-1 cells (ATCC, Manassas, VA) and 
HaCat keratinocytes (a gift from Rivkah Isseroff, University of California, Davis) were 
cultured in DMEM (Lonza, Basel, Switzerland), 10% FBS (Thermo Fisher Scientific, 
Waltham, MA), 2mM L-glutamine, Penicillin/Streptomycin (VWR, Radnor, PA). HaCat 
cells stably overexpressing MARCO and control HaCat cells were generated as previously 
described (Macleod et al., 2013). The Wyeth strain of VV (a kind gift from Michael Croft, 
La Jolla Institute for Allergy and Immunology, CA) vB5R-GFP VV, used for mouse 
experiments (a kind gift from Bernard Moss, National Institute of Allergy and Infectious 
Diseases, National Institutes of Health, MD), and HIV-1 JR-FL PsV (a kind gift from Pascal 
Poignard, International AIDS Vaccine Initiative, La Jolla, CA) were prepared and titered 
from crude extracts of BSC-1 or 293T infected cells, lysed and centrifuged to remove 
cellular debris, and stored at −80°C.
Plaque assays
Cells were infected with VV for 1 hour, then washed and incubated in fresh media for 24 
hours. Plaque formation was visualized by staining cells with crystal violet. MOIs were 
typically selected to give approximately 100–500 plaques per well in a 6-well plate in each 
experiment. All plaques counts were compared to the controls displayed for each individual 
experiments, with plaque counts in the control wells normalized to 100%.
VV infection of murine skin
C57Bl/6 wild-type mice were purchased from the Jackson Laboratory, Bar Harbor, Maine. 
MARCO−/− mice were a gift from Dr. Andrij Holian (Univerity of Montana, MT). All 
animal studies were in accordance with the Public Health Service Policy on Humane Care 
and Use of Laboratory Animals, and were approved by UCSD IACUC (UCSD Animal 
Welfare Assurance # A3033-1). All procedures were performed under isofluorane 
anesthesia, and all efforts were made to minimize pain, discomfort, and suffering. Mice were 
depilated, then infected one day later with 2×106 PFU vB5R-GFP VV by skin scarification, 
25 scratches with a 25 gauge needle within a 1cm2 area on the back. Mice were 
photographed once daily, and lesion sizes were quantified with ImageJ. On day 6 post-
infection, mice were sacrificed and skin from the wound site was biopsied and sent to the 
Moores Cancer Center Histology and Immunohistochemistry Core (La Jolla, CA) for 
fixation, sectioning, and staining with hematoxylin and eosin.
ELISAs
Proteins were bound to EIA/RIA plates at 2.5ug/ml in sterile PBS containing calcium and 
magnesium, pH 7.4 (Lonza, Basel, Switzerland), washed, blocked with PBS containing 
3%BSA, then incubated with VV or HIV-1 PsV diluted in DMEM + 1% FBS. Unbound 
virus was removed by repeated wash steps with PBS. Bound virus was detected using a 
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rabbit polyclonal primary antibody recognizing MARCO (Abcam, Cambridge, MA) or a 
biotinylated human antibody recognizing HIV-1 (a kind gift from Pascal Poignard, 
International AIDS Vaccine Initiative, La Jolla, CA), an HRP-conjugated secondary 
antibody or streptavidin, respectively (Santa Cruz Biotechnology, Santa Cruz, CA), and 
TMB substrate reagent (BD Biosciences Pharmigen, San Diego, CA), and quantified using a 
microplate reader measuring absorbance at 450nm and subtracting absorbance at 570nm. 
Background binding (binding of the same concentrations of VV or HIV-1 PsV to plates 
coated with BSA) was subtracted.
Quantitative realtime PCR
RNA and DNA were isolated using Trizol (Life Technologies, Grand Island, NY), and RNA 
was reverse transcribed using iScript (Bio-Rad, Hercules, CA). Predesigned Taqman 
primers/probes (Life Technologies, Grand Island, NY) were used for the quantification of 
MARCO mRNA and custom Taqman Probes were used for VV DNA-dependent RNA 
polymerase (RPO35) and GAPDH mRNA and DNA quantification using Taqman Gene 
Expression Master Mix (Life Technologies, Grand Island, NY) with a 7300 Real-Time PCR 
System (Life Technologies, Grand Island, NY) using the primer sequences listed below. 
Fold changes of target genes normalized to host cell GAPDH levels relative to the control 
treatments were calculated using the 2(−ΔΔCt) method, with untreated or vehicle treated 
samples normalized to 1 or 100% as indicated.
qPCR Primer/Probe sequences
GAPDH probe: 5′-CATCCATGACAACTTTGGTA-3′. VV RPO35 Probe: 5′-
ATTGAATTCTCTTCCCGCGGATGCTG-3′. Primers were purchased from Sigma-
Aldrich, St. Louis, MO: GAPDH: 5′-CCTAGCACCCCTGGCCAAG-3′, 5′-
TGGTCATGAGTCCTTCCACG-3′; VV RPO35: 5′-GCCAATGAGGGTTCGAGTTC-3′, 
5′-CAACATCCCGTCGTTCATCA-3′;
Reagents
Poly(I:C), Imiquimod, Peptidoglycan and CpG DNA were purchased from Invivogen, San 
Diego, CA. Malp-2 and Flagellin were purchased from Enzo Life Sciences, Farmingdale, 
NY. Bovine serum albumin (BSA), Lipopolysaccharide, Poly(I), Poly(C), Dextran Sulfate, 
and cyclophosphamide were purchased from Sigma-Aldrich, St. Louis, MO. Chloroquine 
phosphate was purchased from Spectrum, Gardena, CA. Recombinant human and mouse 
MARCO, and human OLR1, IL-4, and IL-13 were purchased from R&D Systems, 
Minneapolis, MN.
Stimulation with TLR ligands
HaCat keratinocytes were pretreated for 24 hours with 10μg/ml Poly(I:C), 5μg/ml 
Imiquimod, 5μg/ml CpG DNA, 100ng/ml Malp-2, 1ng/ml Lipopolysaccharide (LPS), 
100ng/ml Flagellin, 1μg/ml Peptidoglycan (PGN), before infection with VV and 
quantification of viral plaque forming units.
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Skin Immunofluorescence staining
All studies were approved by the Human Research Protection program at the University of 
California, San Diego, and were conducted in adherence to the Declaration of Helsinki 
Principles. Written, informed consent was obtained from all donors for all procedures. Skin 
biopsy samples were obtained from normal skin and lesional and non-lesional skin of AD 
patients, frozen in OCT, sectioned using a cryotome, and stored on microscope slides at 
−80°C until use. Briefly, cells were fixed with cold acetone, and stained for the presence of 
MARCO using a monoclonal antibody (a kind gift from Lester Kobzik, Harvard University, 
MA) and Keratin-14 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and 
Alexa-fluor 488- and 568-labeled secondary antibodies, respectively (Life Technologies, 
Grand Island, NY) and counterstained with DAPI. Images were captured using a BX41 
microscope (Olympus, Center Valley, PA).
Statistical Analysis
Analyses were performed using GraphPad Prism version 5.00 for Windows, GraphPad 
Software, San Diego, California, USA, www.graphpad.com.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
AD atopic dermatitis
COLEC12 collectin sub-family member 12
CS chondroitin sulfate
Dxs Dextran sulfate
GAG glycosaminoglycan
HS heparan sulfate
HSPG heparan sulfate proteoglycans
HSV-1 herpes simplex virus type 1
MARCO macrophage receptor with collagenous structure
MSR1 macrophage scavenger receptor 1
NHEK normal human epidermal keratinocytes
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OLR1 oxidized low density lipoprotein (lectin-like) receptor 1
PAMP pattern associated molecular pattern
Poly(C) polycytidylic acid
Poly(I) Polyinosinic acid
Poly(I,C) polyinosinic:polycytidylic acid
PRR pattern recognition receptor
SCARA3 scavenger receptor class A member 3
SCARF1 scavenger receptor class F, member 1
TLR toll-like receptor
VIG vaccinia immune globulins
VV vaccinia virus
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Figure 1. MARCO expression in atopic dermatitis
(a,b) Skin biopsy samples taken from a normal donor and an AD donor at non-lesional and 
lesional sites were analyzed for Keratin-14 (K14), which is predominantly expressed by 
basal keratinocytes, and human MARCO expression, and compared to goat IgG (gIgG) and 
mouse IgG (mIgG) controls. Scale bars = 50μm. Images in (b) are one set of representative 
images from an experiment with 2 normal skin donors and 2 AD donors (see Supplementary 
Fig. S1). (c) NHEK were treated with 50ng/ml IL-4 and/or IL-13 for 24 hours before RNA 
isolation and qPCR for MARCO expression. Error bars indicate SEM, n=3. Differences 
between treatment conditions were not significant, as determined by One-way ANOVA with 
Tukey post-tests.
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Figure 2. Vaccinia binds directly to human and mouse MARCO
Indicated concentrations of VV were added to plates coated with human MARCO 
(hMARCO) (a), mouse MARCO (mMARCO) (b), human OLR1 (d) and human MSR1 (e). 
Virus bound to the immobilized protein was quantified by ELISA. Error bars indicate SEM, 
n=3, with non-linear regressions plotted as solid lines. c, Plates coated with hMARCO were 
incubated with 6×106 PFU/ml VV in the presence of Poly(I). Bound virus was quantified by 
ELISA. Each individual data point is plotted. Data in (c) was transformed using a 
logarithmic x-axis, and the half-maximal inhibitory concentration (IC50) value and the 95% 
confidence interval for this value were calculated using Graphpad Prism. Poly(I) molarity 
was calculated based on the molecular weight of each individual nucleotide in the polymer, 
with average molecules ranging in length up to 1000 nucleotides. f, indicated amounts of 
HIV-1 pseudovirus (PsV) were added to plates coated with hMARCO and bound virus 
quantified by ELISA. Error bars indicate SEM, n=2, with non-linear regression plotted as a 
solid line. a–f, data presented are from one representative experiment of two independent 
experiments.
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Figure 3. Overexpression of MARCO increases VV infection in keratinocytes
Age-matched female Wild-type (WT) and MARCO−/− mice were infected with VV by skin 
scarification, and six days after infection wounds were (a) biopsied for histology and (b) 
sizes were quantified. a, Representative images of the skin of uninfected WT and 
MARCO−/− mice and skin from the edges of the wounds of mice infected with VV are 
displayed. Scale bars = 50μm. b, Wound sizes were quantified with ImageJ, n=12. c, HaCat 
keratinocytes stably overexpressing MARCO (labelled [MARCO]), or control cells 
(pcDNA3) were infected with VV. Plaques were stained and quantified 24 hours after 
infection, n=3. d, HaCat keratinocytes stably overexpressing MARCO (labelled [MARCO]), 
or control cells (pcDNA3) were infected with 1000 PFU/ml VV for 24 hours before 
quantification of viral DNA, n=3. b–d, error bars indicate SEM, all comparisons were made 
using two-tailed Student’s T-tests, ns = not significant, ** P < 0.01, *** P < 0.001. All data 
are from representative experiments repeated at least two times.
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Figure 4. Scavenger receptor antagonists prevent vaccinia infection
HaCat keratinocytes were infected with 100 PFU/well VV in the presence of the indicated 
concentrations of (a) Poly(I:C), Poly(I), and Poly(C), or (b) dextran sulfate (Dxs). Plaques 
were quantified 24 hours after infection. a, Poly(I:C)/Poly(I)/Poly(C) molarities were 
calculated and normalized based on the molecular weight of each individual nucleotide in 
the polymer, with average molecules ranging up to 1000 nucleotides in length. a, two-way 
ANOVA with bonferroni post-tests was used to compare Poly(I) and Poly(I:C) treatment to 
Poly(C) treatment at each concentration, *** P < 0.001. c, HaCat were pretreated with TLR 
ligands for 24 hours before infection with VV. HaCat (d) and NHEK (e,f) were infected 
with VV after Poly(I:C) pretreatment for 24 hours. c–e, plaques were quantified 24 hours 
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after infection. f, Viral mRNA was quantified by qPCR 8 hours after infection. c–f, 
statistical significance was determined using One-way ANOVA with Tukey post-tests, * P < 
0.05, ** P < 0.01, *** P < 0.001, nd, not detectable. g, VV was pretreated for 1 hour at 
37°C with 50μg/ml bovine serum albumin (BSA) or recombinant human MARCO before 
adding to NHEK to assess viral plaque formation. A two-tailed Student’s T-test was used to 
determine statistical significance, *** P < 0.001. a–g, error bars indicate SEM, n=3. h, 50μl 
of PBS, or PBS containing 5mg/ml Poly(I) or Poly(C) were applied to depilated back skin of 
age-matched wild-type female mice for 15 minutes prior to infection with VV. Wound sizes 
were quantified at 6 days post-infection. Error bars indicate SEM, n=4, statistical 
significance determined using One-way ANOVA and a Bonferroni post-test, * P < 0.05.
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